The CPER Resist-omics is a program funded under the 2021–2027 "Contrat Plan Etat-Région" (CPER), a regional and national funding for strategic projects in the the Hauts-de-France Region.
It aims to organize research on inflammatory and infectious diseases, particularly focusing on resistance mechanisms and complications. With steadily rising incidence rates, these two groups of diseases are closely intertwined: they can mutually affect the efficacy of their treatments and lead to complications that compromise the patient’s functional and vital prognosis.
COVID-19 is a prime example: an infection that rapidly triggers an inflammatory response—sometimes severe—and can lead to organ failure, both in the short and long term. Its management underscores the need to combine anti-infective and immunomodulatory approaches.
The Resist-omics program has several major initiatives:
- acquisition of state-of-the-art equipments
- funding scientific research projects on the themes of inflammation and infection
- attracting high-potential researchers
- supporting the dissemination and communication of the program’s results, both in France and internationally
Ultimately, the goal of the Resist-omics CPER is to make the Hauts-de-France region an international leader in research and innovation in the field of infectious and inflammatory diseases, providing new diagnostic, prophylactic, and therapeutic solutions. Clinically, this will result in optimized care pathways for the prevention and management of patients with inflammatory and/or infectious diseases.
project duration
million euros budget
partners : University of Lille, Lille University Hospital, The Pasteur Institute of Lille, Inserm, CNRS
The CPER Resist-omics project receives financial support from the Hauts-de-France Region, the European Union through the European Regional Development Fund (ERDF), the Lille European Metropolis (MEL), the French State and the French National Institute of Health and Medical Research (Inserm).
